bioRxivMicrobiologyPreprint
Evolution of a Functionally Intact but Antigenically Distinct DENV Fusion Loop
R. M. Meganck, D. Zhu, S. Dong, L. J. Snoderly-Foster, Y. R. Dalben, D. J. Thiono, L. J. White, A. M. DeSilva, R. Baric, L. V. Tse
Abstract
A hallmark of Dengue virus (DENV) pathogenesis is the potential for antibody-dependent enhancement, which is associated with deadly DENV secondary infection, complicates the identification of correlates of protection, and negatively impacts the safety and efficacy of DENV vaccines. ADE is linked to antibodies targeting the fusion loop (FL) motif of the envelope protein, which is completely conserved in mosquito-borne flaviviruses and required for viral entry and fusion. In the current study, we utilized saturation mutagenesis and directed evolution to engineer a functional variant with a mutated FL (D2-FL) which is not neutralized by FL-targeting monoclonal antibodies. The FL mutations were combined with our previously evolved prM cleavage site to create a mature version of D2-FL (D2-FLM), which evades both prM- and FL-Abs but retains sensitivity to other type-specific and quaternary cross-reactive (CR) Abs. CR serum from heterotypic (DENV4) infected non-human primates (NHP) showed lower neutralization titers against D2-FL and D2-FLM than isogenic wildtype DENV2 while similar neutralization titers were observed in serum from homotypic (DENV2) infected NHP. We propose D2-FL and D2-FLM as valuable tools to delineate CR Ab subtypes in serum as well as an exciting platform for safer live attenuated DENV vaccines suitable for naive individuals and children.
- organism: non-human primate
- research focus: drug response / drug discovery
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Fusion Loop Modified and Mature Dengue Virus Elicits Protective Serum with Minimal Antibody Dependent Enhancement
Yago R. Dalben, Jacob J. Adler, … Longping V. Tse·bioRxiv·Mar 6, 2026
- An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency
T. Kotaki, T. Kurosu, … M. Kameoka·bioRxiv·Oct 3, 2020
- mRNA-LNP Vaccines Encoding for Dengue Optimized prM/ENV Proteins Induce Protective Immunity without ADE
Enzo LaMontia-Hankin, Clayton J. Wollner, … Justin M. Richner·bioRxiv·Jul 21, 2025
- Cross-reactivity reduced dengue virus serotype 2 vaccine does not confer cross-protection against other serotypes of dengue viruses
J. U. Galula, C.-Y. Yang, … D.-Y. Chao·Future VirologyPeer-reviewed·Mar 23, 2020
- An epitope-resurfaced virus-like particle can induce broad neutralizing antibody against four serotypes of dengue virus
Wen-Fan Shen, Jedhan Ucat Galula, … Day-Yu Chao·bioRxiv·Jun 20, 2018
- A potent neutralizing mouse monoclonal antibody specific to dengue virus type 1 Mochizuki strain recognized a novel epitope around the N-67 glycan on the E protein: a possible explanation of dengue virus evolution regarding the acquisition of N-67 glycan
T. Kotaki, A. Yamanaka, … M. Kameoka·bioRxiv·Oct 3, 2020